Advancing modulator and Treg cell therapies to accelerate clinical translation, redefine immune tolerance, and deliver transformative treatments for autoimmune, inflammatory, and neurodegenerative diseases.
With growing momentum—highlighted by Nobel recognition, Nektar Therapeutics’ clinical progress, and ORCA-T’s potential as the first FDA-approved Treg therapy—Treg therapeutics are entering a pivotal era. The 8th Treg-Directed Therapies Summit gathers leading experts from Quell Therapeutics, Nektar, Sanofi, Yale, and others to address challenges in cell targeting, mechanisms of action, cytokine biology, indication prioritization, GMP and regulatory pathways, clinical trial design, and validated efficacy endpoints to advance Treg therapies toward broader clinical success.
View Event
